Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations. Read more about Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations.
The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda. Read more about The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
The independent effect of drug resistance on T cell activation in HIV infection. Read more about The independent effect of drug resistance on T cell activation in HIV infection.
Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection. Read more about Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection.
Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. Read more about Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men.
Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. Read more about Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection.
Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras. Read more about Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras.
The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. Read more about The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models.
Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. Read more about Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States.
